> Details

Ghafuri, Djamila L.; Abdullahi, Shehu U.; Dambatta, Abdu H.; Galadanci, Jamil; Tabari, Musa A.; Bello-Manga, Halima; Idris, Nura; Inuwa, Hauwa; Tijjani, Aliyu; Suleiman, Aisha A.; Jibir, Binta W.; Gambo, Safiya; Gambo, Awwal I.; Khalifa, Yusuf; Haliru, Lawal; Abdulrasheed, Sani; Zakari, Mohammed A.; Greene, Brittany C.; Trevathan, Edwin; Jordan, Lori C.; Aliyu, Muktar H.; Baumann, Ana A.; DeBaun, Michael R.

Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework
  • Contributor: Ghafuri, Djamila L.; Abdullahi, Shehu U.; Dambatta, Abdu H.; Galadanci, Jamil; Tabari, Musa A.; Bello-Manga, Halima; Idris, Nura; Inuwa, Hauwa; Tijjani, Aliyu; Suleiman, Aisha A.; Jibir, Binta W.; Gambo, Safiya; Gambo, Awwal I.; Khalifa, Yusuf; Haliru, Lawal; Abdulrasheed, Sani; Zakari, Mohammed A.; Greene, Brittany C.; Trevathan, Edwin; Jordan, Lori C.; Aliyu, Muktar H.; Baumann, Ana A.; DeBaun, Michael R.
  • Published: Ovid Technologies (Wolters Kluwer Health), 2022
  • Published in: Journal of Pediatric Hematology/Oncology, 44 (2022) 1, Seite e56-e61
  • Language: English
  • DOI: 10.1097/mph.0000000000002179
  • ISSN: 1077-4114
  • Origination:
  • Footnote:
  • Description: We used the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to evaluate a Stroke Prevention Team’s readiness to prevent strokes in children with sickle cell anemia living in northern Nigeria. The NIH sponsored Stroke Prevention Trial in Nigeria included a goal of a sustainable stroke prevention program. The program’s 1-year reach for transcranial Doppler screening was 14.7% (4710/32,000) of which 6.0% (281/4710) had abnormal velocities (≥200 cm/s). All participants with abnormal transcranial Doppler velocities were started on hydroxyurea (effectiveness). The leaders of all 5 hospitals agreed to adopt the program. After 1 year, program-implementation and maintenance rates were 100%, demonstrating the program’s feasibility and short-term sustainability.